A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia

Research output: Contribution to journalLetter

Original languageEnglish (US)
JournalAmerican Journal of Hematology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Acute Myeloid Leukemia
liposomal doxorubicin
Bortezomib

ASJC Scopus subject areas

  • Hematology

Cite this

@article{0a707e74a5994fccbae40fd37a1798a0,
title = "A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia",
author = "Tomlinson, {Benjamin K.} and Joseph Tuscano and Mehrdad Abedi and Welborn, {Jeanna L} and Mili Arora and O'Donnell, {Robert T} and Theodore Wun and Brian Jonas",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/ajh.25605",
language = "English (US)",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - A phase II study of bortezomib in combination with pegylated liposomal doxorubicin for acute myeloid leukemia

AU - Tomlinson, Benjamin K.

AU - Tuscano, Joseph

AU - Abedi, Mehrdad

AU - Welborn, Jeanna L

AU - Arora, Mili

AU - O'Donnell, Robert T

AU - Wun, Theodore

AU - Jonas, Brian

PY - 2019/1/1

Y1 - 2019/1/1

UR - http://www.scopus.com/inward/record.url?scp=85070921578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070921578&partnerID=8YFLogxK

U2 - 10.1002/ajh.25605

DO - 10.1002/ajh.25605

M3 - Letter

C2 - 31379016

AN - SCOPUS:85070921578

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

ER -